NEWS AND EVENTS
Oct 7, 2025
Averto Medical Awarded $2.1M Grant
Averto Medical, a clinical-stage medical technology company pioneering gastrointestinal disease solutions, today announced it has been awarded a $2.1 million grant from the National Institutes of Health (NIH) to study its flagship product, the ColoSeal™ Intraluminal Colonic Diversion System, for a new indication: diverticulitis.
Feb 25, 2025
Averto Medical Announces FDA Breakthrough Device Designation for ColoSeal™ Intraluminal Colonic Diversion System
Averto Medical, a clinical-stage medical device company pioneering minimally invasive gastrointestinal care, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its ColoSeal™ Intraluminal Colonic Diversion (ICD) System. This designation underscores the potential of ColoSeal™ to significantly improve outcomes for patients undergoing colorectal surgery by eliminating the need for a temporary ostomy.
May 7, 2024
Averto Medical Debuts with Oversubscribed $30M Series A Financing to Advance Innovative Medical Device that Avoids Need for Ostomy
Cormorant Asset Management leads financing with participation from Venrock Healthcare Capital Partners, LifeSci Venture Partners, CVF, and others; Ken Song, MD joins as Executive Chairman with Dan Puckett and Bihua Chen also joining the Board of Directors